Atossa Therapeutics (ATOS, Financial) has entered into a strategic research partnership with Nona Biosciences, a global leader in biotechnology. This collaboration aims to harness Nona's cutting-edge H2L2 Harbour Mice platform to identify promising new therapeutic candidates for breast cancer.
The Harbour Mice platform is renowned for its ability to streamline drug discovery by bypassing the usual requirements for engineering or humanization, which can significantly expedite the development of effective treatments. This innovative platform has already been instrumental in more than 250 drug discovery initiatives across various therapeutic disciplines.
This partnership underscores Atossa's commitment to advancing breast cancer treatment options, leveraging advanced technologies to facilitate the development of next-generation therapies.
